Fortress Biotech, Inc.
FBIONasdaq
$3.36
↓ -1.8%Jul 17 close · end-of-day
Price
1Y↑ +70.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$129.1M
Enterprise Value
-$89.3M
P/E
1.0
P/S
2.0
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$66.2M
Net Income (TTM)
$158.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-84.1%
Net Margin
238.8%
ROE
97.4%
ROIC
—
Debt / Equity
0.2
Net Cash
$218.3M
Return 1Y
+74.1%
Company profile
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also develops late stage product candidates such as intravenous Tramadol for the treatment of post-operative acute pain.
- CEO
- Lindsay A. Rosenwald
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 170
- Headquarters
- Florida
- Website
- fortressbiotech.com
Management & directors
- Jin DavidChief Financial Officer
- Rosenwald Lindsay A MdPRESIDENT, CEO & CHAIRMAN
- Weiss Michael SExecutive Vice Chairman
Roles derived from SEC Form 4 filings.
Earnings
FBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$16.0M↑ +22.1%
Diluted EPS$2.82↓ -687.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$94.3M | -$188.5M | -$203.6M | -$142.3M | -$110.4M | -$70.2M |
| Net income | -$46.5M | -$64.7M | -$86.6M | $31.0M | $21.0M | $37.0M |
| Diluted EPS | — | -$0.79 | -$15.97 | -$8.47 | -$2.69 | -$0.07 |
| Operating cash flow | -$83.7M | -$116.5M | -$179.4M | -$128.2M | -$80.2M | -$65.8M |
| Free cash flow | -$85.6M | -$121.1M | -$182.1M | -$128.3M | -$80.2M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -206.7% | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Net margin | -102.0% | -94.1% | -114.3% | 36.7% | 36.4% | 58.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.9M | $14.6M | $15.1M | $13.1M | $16.4M | $17.6M | $16.1M | $16.0M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$27.8M | -$22.1M | -$23.9M | -$22.3M | -$36.5M | -$6.8M | -$4.6M | -$7.7M |
| Net income | -$10.9M | -$12.9M | $60.2M | -$10.6M | $15.5M | $5.8M | $26.2M | $110.4M |
| Diluted EPS | -$0.73 | -$0.76 | -$0.16 | -$0.48 | $0.45 | $0.11 | -$0.15 | $2.82 |
| Operating cash flow | -$21.8M | -$20.1M | -$12.9M | -$19.6M | -$27.6M | -$6.1M | -$12.5M | $203.9M |
| Free cash flow | — | -$20.1M | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -186.5% | -151.0% | -158.3% | -169.9% | -222.2% | -38.6% | -28.7% | -48.3% |
| Net margin | -73.5% | -88.0% | 398.4% | -80.6% | 94.4% | 33.2% | 163.2% | 688.2% |
Company news
May 18, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Jin David· Chief Financial Officer | Award | 400,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Jin David· Chief Financial Officer | Award | 2,967 | $2.18 | $6,456.19 | filing |
| 2026-03-18 | ROSENWALD LINDSAY A MD· PRESIDENT, CEO & CHAIRMAN | Award | 475,424 | $0.00 | $0.00 | filing |
| 2026-03-18 | WEISS MICHAEL S· Executive Vice Chairman | Award | 475,424 | $0.00 | $0.00 | filing |
| 2026-01-02 | Fortress Biotech, Inc. | Award | 111,209 | $0.00 | $0.00 | filing |
| 2026-01-02 | Fortress Biotech, Inc. | Award | 278,385 | $0.00 | $0.00 | filing |
| 2026-01-01 | Klein Dov | Award | 27,322 | $0.00 | $0.00 | filing |
| 2026-01-01 | Harvey Jimmie | Award | 27,322 | $0.00 | $0.00 | filing |
| 2026-01-01 | Lorenz Kevin | Award | 27,322 | $0.00 | $0.00 | filing |
| 2026-01-01 | Hoenlein Malcolm | Award | 27,322 | $0.00 | $0.00 | filing |
| 2026-01-01 | LOBELL J JAY | Award | 27,322 | $0.00 | $0.00 | filing |
| 2025-10-01 | Jin David· Chief Financial Officer | Award | 2,711 | $1.31 | $3,548.70 | filing |
| 2025-09-29 | Fortress Biotech, Inc. | Award | 59,334 | $0.00 | $0.00 | filing |
Latest 13 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.